Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data ...
(ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in our Phase 3 ENTRUST trial in SHTG,” stated Rohan Palekar, ...
FAT Brands will host a conference call and webcast to discuss its fiscal fourth quarter 2024 financial results today at 4:30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results